20 articles
A next-gen RAS inhibitor called daraxonrasib targets KRAS-mutant cholangiocarcinoma, showing strong preclinical results and early clinical activity.
A comprehensive review reveals how iron-driven cell death can be exploited to treat ATC, one of the most lethal human cancers.
Retrospective study of 120 NSCLC patients finds thymalfasin plus chemoimmunotherapy significantly extends PFS and OS without added toxicity.
Flaxseed compounds enhance PD-1 inhibitor effectiveness against breast cancer through gut bacteria modulation and immune system activation.
Adding an autophagy inhibitor to anlotinib plus PD-1 blockade dramatically reshapes the tumor microenvironment in NSCLC models.
New study reveals how immune cells in tumors deliver protective proteins that block a promising cancer treatment approach.
A once-undruggable cancer driver has finally been targeted, cutting death risk by 60% in a landmark 500-patient trial.
A Phase 2 trial explores whether oral curcumin can enhance Avastin/FOLFIRI chemotherapy outcomes in patients with unresectable colorectal metastases.
A phase 2 trial of datopotamab deruxtecan in 100 NSCLC patients reveals a 26% response rate and critical resistance biomarkers.
Metabolite supplement protects heart from chemo toxicity and enhances tumor suppression in breakthrough dual-action study.
A newly identified enzyme links lactate metabolism to liver cancer progression, and a natural compound delivered via nanoparticles shows striking anti-tumor results.
New research reveals how bone marrow cells produce taurine that feeds leukemia stem cells, offering potential therapeutic targets.
Ginsenoside Rh4 suppresses colorectal cancer by boosting Akkermansia muciniphila and elevating protective bile acid UDCA via FXR signaling.
New research reveals how a liver protein helps tumors evade immune surveillance, opening doors for targeted cancer therapies.
Pyrroloquinoline quinone has demonstrated anticancer activity in preclinical studies, but human cancer trials remain absent. Here's where the science stands.
Researchers report on ezabenlimab treatment combined with chemotherapy and radiation for stage 3 anal cancer patients.
Engineered green tea compound nanoparticles activate cellular powerhouses to suppress tumor growth and improve immune response against melanoma.
A counterintuitive mechanism shows that more NECTIN4 antigen on tumor cells can actually blunt antibody-drug conjugate therapy.
New research reveals how ฮฑ-ketoglutarate regulates AMPK synthesis, offering potential cancer therapy targets through energy stress.
Blocking CysLTR1 reprograms immunosuppressive neutrophils and reverses resistance to anti-PD1 checkpoint therapy in mice.
